Imatinib mesylate
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Myeloid, Chronic Phase
Conditions
Leukemia, Myeloid, Chronic Phase
Trial Timeline
Jun 1, 2005 → Nov 1, 2010
NCT ID
NCT00124748About Imatinib mesylate
Imatinib mesylate is a phase 3 stage product being developed by Novartis for Leukemia, Myeloid, Chronic Phase. The current trial status is terminated. This product is registered under clinical trial identifier NCT00124748. Target conditions include Leukemia, Myeloid, Chronic Phase.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Myeloid, Chronic Phase were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01742299 | Approved | Active |
| NCT00867113 | Phase 2 | Completed |
| NCT00732784 | Phase 1 | Completed |
| NCT01172548 | Phase 2 | Completed |
| NCT01483014 | Phase 2 | Completed |
| NCT00684411 | Phase 2 | Completed |
| NCT01545427 | Phase 2 | Terminated |
| NCT00479934 | Phase 2 | Completed |
| NCT00677092 | Phase 2 | Completed |
| NCT00555581 | Phase 2 | Completed |
| NCT00510354 | Approved | Completed |
| NCT00427583 | Phase 2/3 | Terminated |
| NCT00124748 | Phase 3 | Terminated |
| NCT00171899 | Approved | Completed |
| NCT00171912 | Phase 2 | Completed |
| NCT00171977 | Approved | Completed |
| NCT00171938 | Phase 2 | Terminated |
| NCT00154349 | Phase 2 | Completed |
| NCT00237172 | Phase 2 | Completed |
| NCT00171860 | Phase 2 | Terminated |
Competing Products
20 competing products in Leukemia, Myeloid, Chronic Phase